Vyome (HIND) Competitors $5.30 +0.29 (+5.79%) As of 10/14/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsSEC FilingsShort InterestTrendsBuy This Stock HIND vs. OSRH, LYRA, BTCY, LFWD, CHEK, MHUA, POAI, TNON, INBS, and HSCSShould you be buying Vyome stock or one of its competitors? The main competitors of Vyome include OSR (OSRH), Lyra Therapeutics (LYRA), Biotricity (BTCY), Lifeward (LFWD), Check-Cap (CHEK), Meihua International Medical Technologies (MHUA), Predictive Oncology (POAI), Tenon Medical (TNON), Intelligent Bio Solutions (INBS), and HeartSciences (HSCS). These companies are all part of the "medical equipment" industry. Vyome vs. Its Competitors OSR Lyra Therapeutics Biotricity Lifeward Check-Cap Meihua International Medical Technologies Predictive Oncology Tenon Medical Intelligent Bio Solutions HeartSciences Vyome (NASDAQ:HIND) and OSR (NASDAQ:OSRH) are both small-cap manufacturing companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership. Is HIND or OSRH more profitable? OSR has a net margin of 0.00% compared to Vyome's net margin of -69.71%. OSR's return on equity of -12.19% beat Vyome's return on equity.Company Net Margins Return on Equity Return on Assets Vyome-69.71% -216.95% -69.42% OSR N/A -12.19%-8.18% Do analysts rate HIND or OSRH? Vyome currently has a consensus target price of $15.00, indicating a potential upside of 183.02%. Given Vyome's stronger consensus rating and higher possible upside, equities research analysts clearly believe Vyome is more favorable than OSR.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vyome 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00OSR 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Does the media favor HIND or OSRH? In the previous week, OSR had 2 more articles in the media than Vyome. MarketBeat recorded 4 mentions for OSR and 2 mentions for Vyome. Vyome's average media sentiment score of 1.27 beat OSR's score of 0.63 indicating that Vyome is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vyome 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OSR 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals believe in HIND or OSRH? 22.1% of Vyome shares are owned by institutional investors. Comparatively, 55.3% of OSR shares are owned by institutional investors. 33.0% of Vyome shares are owned by company insiders. Comparatively, 60.6% of OSR shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more risk & volatility, HIND or OSRH? Vyome has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500. Comparatively, OSR has a beta of 1.37, suggesting that its share price is 37% more volatile than the S&P 500. Which has preferable valuation and earnings, HIND or OSRH? OSR has lower revenue, but higher earnings than Vyome. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVyome$303.09K11.77-$7.13M-$433.08-0.01OSR$104.74K112.73-$2.41MN/AN/A SummaryOSR beats Vyome on 9 of the 14 factors compared between the two stocks. Get Vyome News Delivered to You Automatically Sign up to receive the latest news and ratings for HIND and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HIND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HIND vs. The Competition Export to ExcelMetricVyomeSurgical, Medical, And Dental Instruments And Supplies IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$3.37M$173.11M$2.50B$10.50BDividend YieldN/AN/A2.53%4.80%P/E Ratio-0.011.8826.0827.24Price / Sales11.775.65319.26196.48Price / CashN/A3.7747.0861.53Price / Book-0.151.4937.196.74Net Income-$7.13M-$51.31M$6.97M$276.59M7 Day Performance-9.71%-4.68%-1.22%-0.47%1 Month PerformanceN/A-5.94%0.49%7.47%1 Year PerformanceN/A253.68%69.66%34.58% Vyome Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HINDVyome2.7463 of 5 stars$5.30+5.8%$15.00+183.0%N/A$3.37M$303.09K-0.0150OSRHOSRN/A$0.61-4.7%N/AN/A$13.71MN/A0.00N/ANews CoverageGap UpLYRALyra Therapeutics2.9532 of 5 stars$7.59-6.2%$100.00+1,217.5%-33.8%$13.30M$1.53M-0.2650News CoverageHigh Trading VolumeBTCYBiotricityN/A$0.48-2.1%N/A+154.3%$12.83M$12.06M-0.4440Gap UpLFWDLifeward2.4393 of 5 stars$0.80-0.4%$9.00+1,027.1%-71.8%$12.59M$25.66M-0.2660News CoverageCHEKCheck-Cap0.2267 of 5 stars$2.13+0.9%N/A+32.2%$12.35MN/A-0.7180Negative NewsMHUAMeihua International Medical Technologies1.0596 of 5 stars$0.37-2.3%N/A-46.7%$12.12M$96.90M0.00620News CoveragePOAIPredictive Oncology1.1312 of 5 stars$14.26-0.3%N/A+47.2%$10.91M$1.62M-4.6830TNONTenon Medical2.1168 of 5 stars$1.18+0.9%$5.50+366.1%-64.1%$10.39M$3.28M-0.048INBSIntelligent Bio Solutions1.3744 of 5 stars$1.09-4.4%N/A-25.5%$10.35M$3.05M-0.5310HSCSHeartSciences2.3544 of 5 stars$3.73-0.5%$10.50+181.5%-1.1%$9.93MN/A-0.4510Analyst ForecastGap Down Related Companies and Tools Related Companies OSR Alternatives Lyra Therapeutics Alternatives Biotricity Alternatives Lifeward Alternatives Check-Cap Alternatives Meihua International Medical Technologies Alternatives Predictive Oncology Alternatives Tenon Medical Alternatives Intelligent Bio Solutions Alternatives HeartSciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HIND) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredA Huge Shift Is Underway in AmericaWall Street legend issues chilling new warning: "I've never seen anything as dangerous as this" The man who...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vyome Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vyome With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
